DALLAS, Dec. 14, 2018 (GLOBE NEWSWIRE) — — via OTC PR WIRE – Puration, Inc. () (“PURA”) today announced a 100 pallet Telluride Happy Water order and marketing campaign. The order is going to Austin, Texas to the same distributor that order twelve pallets last month. Reaction to the initial order has been good and the distributor has expanded its order. The distributor and PURA will meet next week in PURA’s Dallas headquarters to plan an associated marketing campaign to be coordinated with the retail sales of Telluride Happy Water.
Management is working diligently for Puration to realize over $1 million in sales for 2018. Management believes the company is on track to exceed that goal.
Telluride Happy Water is refreshing and delicious drink that enhances the cannabis experience as a beverage before partaking or during when used in a water-pipe. Telluride Happy Water has a higher level of dissolved oxygen in it than almost any bottled water on the market. A patented technology and formula reduces the size of water molecules which creates a platform that accelerates the uptake of anything mixed with or filtered through the patented water technology. This is how Telluride Happy Water exponentially increases a cannabis high.
Puration recently released an with details on the recent acquisition of the Telluride Health Company and the plans for integrating the operation into PURA’s overall cannabis beverage business model.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company‘s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies‘ contracts, the companies‘ liquidity position, the companies‘ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.